These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. When--and how--to use an oral agent. Shuman CR Med Times; 1980 May; 108(5):77-81, 85-6. PubMed ID: 7374409 [No Abstract] [Full Text] [Related]
43. Oral hypoglycemic drugs: should they be used? Two views. Howard WJ; Savage PJ Ariz Med; 1978 Aug; 35(8):549-51. PubMed ID: 697600 [No Abstract] [Full Text] [Related]
44. [Pharmacologic study with glisoxepide and other blood sugar reducing sulfonamide derivatives in metabolically healthy subjects and diabetics]. Haupt E; Beyer J; Schöffling K Arzneimittelforschung; 1974 Mar; 24(0):418-25. PubMed ID: 4211557 [No Abstract] [Full Text] [Related]
46. [Experimental and clinical pharmacology of oral antidiabetics]. Cuomo V; Marino A Clin Ter; 1972 Sep; 62(6):505-52. PubMed ID: 4674507 [No Abstract] [Full Text] [Related]
47. [Progress in oral antidiabetic therapy]. Rambert P Therapeutique; 1973 Nov; 49(9):555-6. PubMed ID: 4600034 [No Abstract] [Full Text] [Related]
48. Probing of specific binding of synthetic sulfonylurea with the insulinoma cell line MIN6. Park KH; Akaike T J Biochem; 2005 Jul; 138(1):21-5. PubMed ID: 16046444 [TBL] [Abstract][Full Text] [Related]
49. [Oral antidiabetic agents: what are the choices?]. Crausaz FM Rev Med Suisse Romande; 1991 Aug; 111(8):701-5. PubMed ID: 1925244 [No Abstract] [Full Text] [Related]
50. Oral agent therapy in the treatment of type 2 diabetes. Feinglos MN; Bethel MA Diabetes Care; 1999 Apr; 22 Suppl 3():C61-4. PubMed ID: 10189564 [No Abstract] [Full Text] [Related]
51. [Cyclohexamide. A new oral hypoglycemic agent]. Villaseñor A; Parra A; López Amor E; Rull JA; Lozano-Castañeda O Rev Invest Clin; 1967; 19(2):149-57. PubMed ID: 5317602 [No Abstract] [Full Text] [Related]
53. [Action of the sulfonylureas tolbutamide and glypentide on the lacticdehydrogenase plasma levels (author's transl)]. García-Rafanell J; Morell-Mestre J Rev Esp Fisiol; 1974 Jun; 30(2):91-6. PubMed ID: 4421448 [No Abstract] [Full Text] [Related]
54. Beyond sulfonylureas: new oral medications in the treatment of NIDDM (type II DM). Capriotti T Medsurg Nurs; 1997 Jun; 6(3):166-9. PubMed ID: 9238992 [No Abstract] [Full Text] [Related]
55. [Glipizide, a new sulfonylurea in the treatment of diabetes mellitus]. Villaseñor A Prensa Med Mex; 1973; 38(5):211-4. PubMed ID: 4782089 [No Abstract] [Full Text] [Related]
56. Oral hypoglycemic agents: the pharmacological basis of their clinical use. Davidoff F R I Med J; 1973 Oct; 56(10):409-14. PubMed ID: 4518221 [No Abstract] [Full Text] [Related]
57. [Indications and limitations of oral hypoglycemic agents in the treatment of diabetes mellitus]. Guillon J; Charbonnel B Cah Med; 1972 Nov; 13(14):999-1006. PubMed ID: 4646244 [No Abstract] [Full Text] [Related]
59. [Relationship between hypoglycemic activity and binding ability with bovine serum albumin of sulfonylurea related compounds (author's transl)]. Yoshitomi H; Nakayama T; Goto S Yakugaku Zasshi; 1981 Oct; 101(10):926-31. PubMed ID: 7338790 [No Abstract] [Full Text] [Related]
60. [Comparative effect of various hypoglycemic sulfonylurea compounds on thyroid function in the rat]. ZIZINE L Ann Endocrinol (Paris); 1957; 18(4):673-5. PubMed ID: 13498450 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]